Researchers from Brigham and Women’s Hospital (MA, USA) report a new quantitative technique, based on measuring the fraction of T cells in a tumor sample, that could be used to predict the risk of melanoma recurrence.
Scientists based at the German Center for Infection Research (DZIF) at Charité, Universitätsmedizin Berlin (Germany) have developed a new assay to detect the 2019 novel Chinese coronavirus.
Researchers based at University of Texas Medical Branch (TX, USA) report the use of quantitative proteomics studies to identify a potential biomarker for rickettsial infections, including Mediterranean spotted fever and Rocky Mountain spotted fever.
Researchers discovered in a study of 15 healthy, young men that were deprived of one night’s sleep, that the plasma concentration of Alzheimer’s disease biomarker – tau – is increased on average by 17% compared to participants who were not sleep deprived.
As we enter 2020, Bioanalysis Zone cast a reflective eye over another exciting year in the bioanalytical field. In this editorial we breakdown the year into the ABCs of bioanalysis, covering the top interviews, news, discussion and conferences that 2019 had to offer.
Thermo Fisher Scientific (MA, USA) and Agilent Technologies (CA, USA) renew their commitment to the Instrument Control Exchange Program, which aims to improve workflow efficiency by allowing users to select hardware and software that most appropriately meet their application needs.
Researchers from Pennsylvania State University (PA, USA) and New York University (NY, USA) have developed a portable microfluidic device coupled to Raman spectroscopy that could be used to rapidly and inexpensively capture and identify viruses.
Researchers have developed a fast and inexpensive paper-based blood test that could diagnose Lyme disease soon after infection. The test exhibited high levels of specificity and sensitivity when tested on blood samples from 50 individuals with or without Lyme disease.
Charles River Laboratories (MA, USA) are set to expand into the rapidly growing cell therapy market through the acquisition of human-derived cellular product producer, HemaCare Corporation (CA, USA).